Reported Saturday, Bicycle Therapeutics Announced Updated Phase 1/2 Results For Zelenectide Pevedotin (Formerly BT8009) In Metastatic Urothelial Cancer, BT5528 In Advanced Solid Tumors And BT7480 In Advanced Solid Tumors
Reported Saturday, Bicycle Therapeutics Announced Updated Phase 1/2 Results For Zelenectide Pevedotin (Formerly BT8009) In Metastatic Urothelial Cancer, BT5528 In Advanced Solid Tumors And BT7480 In Advanced Solid Tumors
據週六報道，愛文思控股宣佈了Zelenectide Pevedotin（原名BT8009）在轉移性膀胱上皮癌，BT5528 在愛文思控股和BT7480在愛文思控股的更新的1/2期結果。
- Updated monotherapy data for Nectin-4 targeting zelenectide pevedotin in metastatic urothelial cancer (mUC) showed a promising 45% overall response rate (ORR), 11.1 months median duration of response, and a generally well-tolerated safety profile
- EphA2-targeting BT5528 demonstrated an emerging differentiated safety profile and antitumor activity in patients with advanced solid tumors, including a 45% ORR in mUC 6.5 mg/m2 every two weeks-dose expansion cohort
- Relatively low frequency and severity of treatment-related peripheral neuropathy following monotherapy with Bicycle Toxin Conjugates zelenectide pevedotin and BT5528, with patients often able to continue therapy without modification
- BT7480 demonstrated a favorable safety profile and preliminary antitumor activity in advanced Nectin-4-associated solid tumors
- 針對轉移性膀胱癌（mUC）的Nectin-4靶向zelenectide pevedotin的單藥療法數據更新顯示，有希望的45%總體反應率（ORR），11.1個月的中位反應持續時間，以及一般耐受性良好的安全性概況
- EphA2靶向藥BT5528在愛文思控股固體腫瘤患者中展示出新興的差異化安全概況和抗腫瘤活性，包括在轉移性膀胱癌中45%的ORR，在每兩週6.5毫克/平方米的劑量擴展隊列中
- 使用單獨治療的Bicycle毒素結合物zelenectide pevedotin和BT5528時，治療相關性周圍神經病變的發生率和嚴重程度相對較低，患者通常可以在不調整治療方案的情況下繼續接受治療。
- BT7480在晚期Nectin-4相關實體瘤中顯示出有利的安全性和初步的抗腫瘤活性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間